CN101743239A - 氰基异喹啉 - Google Patents
氰基异喹啉 Download PDFInfo
- Publication number
- CN101743239A CN101743239A CN200880021250A CN200880021250A CN101743239A CN 101743239 A CN101743239 A CN 101743239A CN 200880021250 A CN200880021250 A CN 200880021250A CN 200880021250 A CN200880021250 A CN 200880021250A CN 101743239 A CN101743239 A CN 101743239A
- Authority
- CN
- China
- Prior art keywords
- dimethoxy
- isoquinoline
- nitrile
- piperazine
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200701348 | 2007-09-19 | ||
DKPA200701348 | 2007-09-19 | ||
PCT/DK2008/050225 WO2009036766A1 (fr) | 2007-09-19 | 2008-09-18 | Cyanoisoquinoléine |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101743239A true CN101743239A (zh) | 2010-06-16 |
Family
ID=40011353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880021250A Pending CN101743239A (zh) | 2007-09-19 | 2008-09-18 | 氰基异喹啉 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2203438A1 (fr) |
JP (1) | JP2010539195A (fr) |
CN (1) | CN101743239A (fr) |
AR (1) | AR068466A1 (fr) |
CA (1) | CA2691474C (fr) |
CL (1) | CL2008002809A1 (fr) |
TW (1) | TW200918519A (fr) |
WO (1) | WO2009036766A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858620B2 (en) * | 2007-09-19 | 2010-12-28 | H. Lundbeck A/S | Cyanoisoquinoline |
TW201215607A (en) * | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
BR112013021180A2 (pt) * | 2011-02-18 | 2019-09-24 | Allergan Inc | derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a) |
US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
CA2852820A1 (fr) | 2011-11-09 | 2013-05-16 | AbbVie Deutschland GmbH & Co. KG | Carboxamides heterocycliques utiles comme inhibiteurs de la phosphodiesterase de type 10a |
UY34980A (es) | 2012-08-17 | 2014-03-31 | Abbvie Inc | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |
KR20150056844A (ko) | 2012-09-17 | 2015-05-27 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 포스포디에스테라제 타입 10a의 신규 억제제 화합물 |
WO2014071044A1 (fr) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a) |
US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
MX2015012008A (es) | 2013-03-14 | 2016-04-15 | Abbvie Deutschland | Compuestos inhibidores novedosos de fosfodiesterasa tipo 10a. |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
US20210379061A1 (en) | 2018-09-28 | 2021-12-09 | Takeda Pharmaceutical Company Limited | Balipodect for treating or preventing autism spectrum disorders |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004041258A2 (fr) * | 2002-10-30 | 2004-05-21 | Neuro3D | Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie |
WO2005003129A1 (fr) * | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolodihydroisoquinolines comme inhibiteurs de pde10 |
WO2005012485A2 (fr) * | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a |
WO2005120514A1 (fr) * | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique |
WO2006011040A1 (fr) * | 2004-07-23 | 2006-02-02 | Pfizer Products Inc. | Derives quinazolin-4-yl- piperidine et cinnolin-4-yl-piperidine utilises en tant qu'inhibiteurs de pde10 pour le traitement de troubles du snc |
WO2007103554A1 (fr) * | 2006-03-08 | 2007-09-13 | Amgen Inc. | Dérivés de quinoline et d'isoquinoline en tant qu'inhibiteurs de phosphodiestérase 10 |
-
2008
- 2008-09-09 TW TW097134479A patent/TW200918519A/zh unknown
- 2008-09-17 AR ARP080104039A patent/AR068466A1/es unknown
- 2008-09-18 JP JP2010525197A patent/JP2010539195A/ja not_active Ceased
- 2008-09-18 CA CA2691474A patent/CA2691474C/fr not_active Expired - Fee Related
- 2008-09-18 EP EP08801401A patent/EP2203438A1/fr not_active Withdrawn
- 2008-09-18 CN CN200880021250A patent/CN101743239A/zh active Pending
- 2008-09-18 WO PCT/DK2008/050225 patent/WO2009036766A1/fr active Application Filing
- 2008-09-22 CL CL2008002809A patent/CL2008002809A1/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004041258A2 (fr) * | 2002-10-30 | 2004-05-21 | Neuro3D | Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie |
WO2005003129A1 (fr) * | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolodihydroisoquinolines comme inhibiteurs de pde10 |
WO2005012485A2 (fr) * | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a |
WO2005120514A1 (fr) * | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique |
WO2006011040A1 (fr) * | 2004-07-23 | 2006-02-02 | Pfizer Products Inc. | Derives quinazolin-4-yl- piperidine et cinnolin-4-yl-piperidine utilises en tant qu'inhibiteurs de pde10 pour le traitement de troubles du snc |
WO2007103554A1 (fr) * | 2006-03-08 | 2007-09-13 | Amgen Inc. | Dérivés de quinoline et d'isoquinoline en tant qu'inhibiteurs de phosphodiestérase 10 |
Also Published As
Publication number | Publication date |
---|---|
CA2691474A1 (fr) | 2009-03-26 |
EP2203438A1 (fr) | 2010-07-07 |
WO2009036766A1 (fr) | 2009-03-26 |
CA2691474C (fr) | 2013-09-10 |
AR068466A1 (es) | 2009-11-18 |
JP2010539195A (ja) | 2010-12-16 |
CL2008002809A1 (es) | 2009-11-27 |
TW200918519A (en) | 2009-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101743239A (zh) | 氰基异喹啉 | |
EP2057153B1 (fr) | Derivés (3-aryl-piperazin-1-yl) de la 6,7-dialcoxyquinazoline, 6,7-dialcoxyphtalazine et 6,7-dialcoxyisoquinoline | |
US8841297B2 (en) | Phenylimidazole derivative as PDE10A enzyme inhibitor | |
JP5768044B2 (ja) | Pde10a酵素阻害剤としての新規のフェニルイミダゾール誘導体 | |
JP5502890B2 (ja) | ピリダジノン誘導体 | |
JP5698761B2 (ja) | 酵素pde10a阻害剤としての2−アリールイミダゾール誘導体 | |
KR101363091B1 (ko) | 헤테로아릴 치환된 피리다지논 유도체 | |
KR20150037950A (ko) | 4-메틸-2,3,5,9,9b-펜타아자-사이클로펜타[a]나프탈렌 | |
JP2013505911A (ja) | ホスホジエステラーゼ10a阻害剤としてのイミダゾピリジンまたはイミダゾピリミジン誘導体 | |
CN102741250A (zh) | 作为pde10a酶抑制剂的杂芳族苯基咪唑衍生物 | |
Jankowska et al. | Advances in discovery of PDE10A inhibitors for CNS-related disorders. Part 1: overview of the chemical and biological research | |
US7858620B2 (en) | Cyanoisoquinoline | |
CN101155787B (zh) | (3,4-二氢-喹唑啉-2-基)-茚满-1-基-胺 | |
CN103874701A (zh) | 吡啶化合物和其用途 | |
KR20110029653A (ko) | 포스포디에스테라제 저해 활성을 가지는 화합물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1144575 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100616 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1144575 Country of ref document: HK |